Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
infection
Biotech
Seres shrinks head count by 25% to fund biotherapeutic's ph. 2
Seres is laying off a quarter of its workforce as the microbiome biopharma conserves resources to take its infection preventive therapy into phase 2.
James Waldron
Sep 23, 2025 10:00am
Recce's synthetic gel treats skin infections in ph. 2
Feb 19, 2025 8:39am
X4 scores a phase 3 win for immune deficiency disorder drug
Nov 30, 2022 10:45am
Could a single pill outsmart a tumor's resistance mechanisms?
Mar 29, 2021 10:00am
Gilead snaps ups German virology biotech MYR
Dec 10, 2020 8:55am
Takeda's maribavir hits phase 3 goal
Dec 4, 2020 8:47am
